ThromboGenics NV is a Belgium-based biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing new medicines to treat visual disorders, cardiovascular diseases and cancer. Its main product is Microplasmin, a proteolytic enzyme in Phase II trials, which is used as a surgical adjunct for vitrectomy and as a potential non-surgical treatment for a number of blinding eye diseases, such as macular holes and diabetic macular edema (DME). As of December 31, 2008, ThromboGenics NV had two wholly owned subsidiaries: ThromboGenics Inc. in the United States and ThromboGenics Ltd in Ireland.
Research Alerts:
Receive alerts on the latest reports on ThromboGenics NV
Subscribe to Research Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
